EmCRT P5 peptide identified as C1q-binding site, suppressing classical complement pathway and neutrophil functions
Background
Alveolar echinococcosis is a severe parasitic disease caused by Echinococcus multilocularis larvae, which employ sophisticated immune evasion tactics to survive within the host. One such strategy involves the parasite's calreticulin (EmCRT), previously shown to bind human complement component C1q and inhibit C1q-initiated complement activation. Understanding this interaction is crucial, as the complement system is a primary defense mechanism. The specific gap addressed by this study was to precisely identify the C1q-binding site on EmCRT to elucidate the molecular mechanism of immune evasion.
Study Design
Researchers employed a systematic approach to pinpoint the C1q-binding site on EmCRT. They first expressed overlapping fragments of EmCRT and conducted functional assays to narrow down the active region. This led to the identification of the EmCRT-S1 fragment, encompassing amino acids 140-204. Subsequently, overlapping synthetic peptides covering this EmCRT-S1 region were synthesized and tested for C1q binding. The P5 peptide (EmCRT160-174 aa) was then evaluated for its ability to suppress C1q-mediated classical complement pathway activation and C1q-induced neutrophil functions, including chemotaxis, reactive oxygen species (ROS) production, cathepsin G release, and myeloperoxidase activity.
Results
The initial fragment expression and functional assays successfully narrowed the C1q-binding site to the EmCRT-S1 fragment, located between amino acids 140 and 204 of EmCRT. Further investigation with synthetic peptides precisely pinpointed the binding site to the P5 peptide, corresponding to amino acids 160-174 of EmCRT. This P5 peptide demonstrated significant immunomodulatory activity. Specifically, the binding of P5 peptide to C1q markedly suppressed the activation of the C1q-mediated classical complement pathway. Beyond complement inhibition, the P5 peptide also significantly inhibited several C1q-induced neutrophil biological functions. These included a marked reduction in neutrophil chemotaxis, decreased production of reactive oxygen species, and suppressed release of both cathepsin G and myeloperoxidase.
Key Findings
- The C1q-binding site on Echinococcus multilocularis calreticulin (EmCRT) was narrowed to the EmCRT-S1 fragment (amino acids 140-204).
- The precise C1q-binding site was pinpointed to the P5 peptide (EmCRT160-174 aa).
- Binding of P5 peptide to C1q markedly suppressed activation of the
C1q-mediated classical complement pathway. - P5 peptide inhibited
C1q-induced neutrophilchemotaxisandreactive oxygen speciesproduction. - P5 peptide suppressed
C1q-induced release ofcathepsin Gandmyeloperoxidasefrom neutrophils.
Why It Matters
Identifying the EmCRT P5 peptide as the precise C1q-binding site provides a critical molecular target for disrupting Echinococcus multilocularis's immune evasion strategy. This discovery opens two significant avenues: first, for the development of novel vaccines against echinococcosis that could block the parasite's ability to inactivate host complement, thereby enhancing immune clearance. Second, the C1q-inhibitory properties of P5 peptide suggest its potential as a therapeutic drug for complement-associated inflammatory or autoimmune diseases, where excessive complement activation contributes to pathology. While currently preclinical, this work offers a specific peptide sequence that could be engineered for future therapeutic or prophylactic applications, moving beyond broad immunomodulation to targeted molecular intervention.
echinococcosis
parasitic-disease
immune-evasion
complement-system
c1q
emcrt